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Abstract
Background
First-degree relatives (FDR) of patients with colorectal cancer have a higher risk of develop-
ing colorectal cancer than the general population. For this reason, screening guidelines rec-
ommend colonoscopy every 5 or 10 y, starting at the age of 40, depending on whether
colorectal cancer in the index-case is diagnosed at <60 or60 y, respectively. However,
studies on the risk of neoplastic lesions are inconclusive. The aim of this study was to deter-
mine the risk of advanced neoplasia (three or more non-advanced adenomas, advanced
adenoma, or invasive cancer) in FDR of patients with colorectal cancer compared to aver-
age-risk individuals (i.e., asymptomatic adults 50 to 69 y of age with no family history of
colorectal cancer).
Methods and Findings
This cross-sectional analysis includes data from 8,498 individuals undergoing their first life-
time screening colonoscopy between 2006 and 2012 at six Spanish tertiary hospitals. Of
these individuals, 3,015 were defined as asymptomatic FDR of patients with colorectal can-
cer (“familial-risk group”) and 3,038 as asymptomatic with average-risk for colorectal cancer
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(“average-risk group”). The familial-risk group was stratified as one FDR, with one family
member diagnosed with colorectal cancer at60 y (n = 1,884) or at <60 y (n = 831), and as
two FDR, with two family members diagnosed with colorectal cancer at any age (n = 300).
Multiple logistic regression analysis was used for between-group comparisons after adjust-
ing for potential confounders (age, gender, and center). Compared with the average-risk
group, advanced neoplasia was significantly more prevalent in individuals having two FDR
with colorectal cancer (odds ratio [OR] 1.90; 95% confidence interval [CI] 1.36–2.66, p <
0.001), but not in those having one FDR with colorectal cancer diagnosed at60 y (OR
1.03; 95% CI 0.83–1.27, p = 0.77) and <60 y (OR 1.19; 95% CI 0.90–1.58, p = 0.20). After
the age of 50 y, men developed advanced neoplasia over two times more frequently than
women and advanced neoplasia appeared at least ten y earlier. Fewer colonoscopies by 2-
fold were required to detect one advanced neoplasia in men than in women.
Major limitations of this study were first that although average-risk individuals were con-
secutively included in a randomized control trial, this was not the case for all individuals in
the familial-risk cohort; and second, the difference in age between the average-risk and
familial-risk cohorts.
Conclusions
Individuals having two FDR with colorectal cancer showed an increased risk of advanced
neoplasia compared to those with average-risk for colorectal cancer. Men had over 2-fold
higher risk of advanced neoplasia than women, independent of family history. These data
suggest that screening colonoscopy guidelines should be revised in the familial-risk
population.
Introduction
Clinical guidelines recommend more intensive surveillance in first-degree relatives (FDR) of
patients with colorectal cancer than in average-risk individuals, as their risk of developing colo-
rectal cancer is 2- to 4-fold higher [1–4]. Screening in this population is recommended from
the age of 40 or 10 y before the youngest case in the immediate family, since the disease tends
to develop about 10 y earlier in FDR than in the general population [5]. Colonoscopy every 5
[3,6–8] or 10 [3] y, depending on the number of relatives affected and age at cancer diagnosis,
is the predominant screening strategy for these individuals, as it is the most effective procedure
to detect and remove advanced adenomas. However, this recommendation is not supported by
prospective studies.
Low-penetrance genetic alterations may favor earlier development of advanced adenomas
or accelerate the transition from adenoma to carcinoma, increasing the risk of colorectal cancer
in this population [9]. If so, this should be reflected in a higher prevalence and an earlier onset
of advanced adenomas in FDRs of patients with colorectal cancer than in average-risk individ-
uals (i.e., asymptomatic individuals over 50 y). However, the results of several studies are
inconclusive. Some show an increased prevalence of advanced adenoma but are questionable
due to small sample size [10] or a retrospective design [11,12], based on registries that could
introduce a selection bias because they included patients with hereditary colorectal cancer syn-
dromes, indication of colonoscopy was not specifically ascertained, and information on
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colonoscopy quality was not documented. On the other hand, few prospective studies that
have specifically addressed this issue were underpowered to stratify for familial risk or did not
include appropriate average-risk individuals [13–17]. Indeed, there is little evidence supporting
the notion that the natural history and prognosis of non-syndromic familial colorectal cancer
and sporadic colorectal cancer may differ. Overall, evidence only favors screening at a younger
age in familial-risk individuals [5]. In fact, there are no large-scale studies comparing the preva-
lence of advanced adenomas in asymptomatic familial- and average-risk individuals stratified
by number of affected relatives, age and gender. Therefore, clarification on this issue in differ-
ent familial-risk groups is crucial to guide future screening recommendations for this
population.
The current study aimed to compare the neoplastic findings on first screening colonoscopy
and the predicted probability of advanced adenoma or cancer according to age and gender
between asymptomatic FDR of patients with colorectal cancer and average-risk individuals.
Methods
Analysis Plan
The current study was planned in March 2011 as a post-hoc analysis of three prospective stud-
ies [18–20]: one study that assessed the perfomance of fecal immunochemical testing in asymp-
tomatic FDR of patients with colorectal cancer [18], one randomized control trial (RCT) that
assessed the efficacy of fecal immunochemical testing and colonoscopy as screening methods
in asymptomatic FDR of patients with colorectal cancer [19], and one RCT that assessed the
efficacy of fecal immunochemical testing and colonoscopy as screening methods in asymptom-
atic average-risk individuals [20]. Patient recruitment was completed by December 2011 and
all colonoscopies were finished by March 2012. The database audit was carried out by EQ and
FB and queries were solved between June 2013 and February 2014. Finally, data were analyzed
between March and September 2014.
Study Design and Setting
The study includes prospectively collected cross-sectional data from asymptomatic whites
undergoing their first lifetime screening colonoscopy between January 2006 and March 2012
(Fig 1), attended at six Spanish tertiary hospitals with specific high-risk colorectal cancer clinics
responsible for the management of patients with hereditary colorectal cancer syndromes and
familial colorectal cancer. In the two studies including asymptomatic familial-risk individuals
the recruitment period was from January 2006 to December 2010 [19] and from January 2010
to December 2011 [18], respectively. In the RCT including asymptomatic average-risk individ-
uals the recruitment period was initiated in June 2009, and finished in June 2011.
Study Sample
An asymptomatic familial-risk group comprising 4,175 asymptomatic FDR of patients with
non-syndromic colorectal cancer was created by combining data from multiple sources: 2,322
(55.6%) of the individuals were consecutively included in two prospective trials [18,19]
designed to analyze the efficacy of fecal immunochemical testing to detect advanced neoplasia,
and the remaining FDR (n = 1,853; 44.4%) were recruited from those attending their respective
colorectal cancer high-risk outpatient clinics due to family history of colorectal cancer, to com-
plete sample size requirements. These individuals were mainly referred either by primary care
physicians or colleagues from the oncology and surgery departments following local referring
protocols. Screening recommendations for individuals with family history of colorectal cancer
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were based on the Spanish Clinical Practice Guideline for colorectal cancer screening [6]. In
summary, colonoscopy every 5 y from age 40 (or 10 y before the youngest case in the immedi-
ate family) is recommended for individuals with one FDR with colorectal cancer diagnosed
before the age of 60 or two or more FDR with colorectal cancer (regardless of age), and colo-
noscopy every 10 y from age 40 (or 10 y before the youngest case in the immediate family) for
individuals with one FDR diagnosed over the age of 60. Baseline and outcome data from FDR
included at colorectal cancer high-risk outpatient clinics were prospectively collected in an
anonymized database, according to the Spanish personal data protection law.
A second group of asymptomatic individuals with average risk of colorectal cancer, served
as a control group, and included 4,323 asymptomatic average-risk individuals (adults 50 to 69
y of age with no family history of colorectal cancer) assigned to the colonoscopy arm in the
COLONPREV trial [20], a RCT designed to compare the efficacy of colonoscopy and biennial
fecal immunochemical testing for reducing colorectal cancer-related mortality in the average-
risk population. The study protocol is available online (www.nejm.org/doi/suppl/10.1056/
NEJMoa1108895/suppl_file/nejmoa1108895_appendix.pdf) [20].
FDR of patients with colorectal cancer was determined during an interview by a gastroenter-
ologist and using a questionnaire on demographic data as well as their own medical and family
history of cancer at each participant center. Recruitment of individuals in the average-risk
Fig 1. Study enrollment and outcomes. Asymptomatic average-risk individuals and familial-risk individuals undergoing their first lifetime screening
colonoscopy were prospectively included in the six participating centers. All had high-quality colonoscopies (good or excellent bowel cleansing and cecal
intubation).
doi:10.1371/journal.pmed.1002008.g001
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cohort has been previously described and included a personal interview about personal and
family history of neoplasia performed at the local colorectal cancer screening office [20].
Inclusion criteria for the familial-risk group were the following: age 40–69 or 10 y younger
than the youngest case in the family; complete colonoscopy (good or excellent bowel cleansing
and cecal intubation), and colorectal cancer confirmed by written medical report. In the aver-
age-risk cohort, inclusion criteria were the following: age 50–69 y and no family history of colo-
rectal neoplasia [20].
Exclusion criteria for both groups included the following: personal history of colorectal neo-
plasia, inflammatory bowel disease, familial history of hereditary colorectal cancer, abdominal
symptoms needing further investigation, previous colorectal cancer screening with any tech-
nique, severe comorbidity, or refusal to participate.
Ethics Statement
The Clinical Research Ethics Committee of Hospital Clinic de Barcelona approved the study.
The Ethical Committee of Hospital Universitario de Canarias [19] and the Galician Clinical
Research Ethics Committee [18] approved the two studies involving familial-risk individuals
The ethics committees of the 15 tertiary hospitals participating in the RCT involving average-
risk individuals approved the study protocol. All participants belonging to the referred clinical
trials [18–20] provided written informed consent and all authors had access to the study data
and reviewed and approved the final manuscript. Familial-risk individuals included at the colo-
rectal cancer high-risk outpatient clinics did not provide informed consent as they were waived
by the IRB of Hospital Clinic de Barcelona.
Data Collection
In the familial-risk cohort, age, sex, number of relatives with colorectal cancer, kinship, and
index-case age at diagnosis of colorectal cancer were recorded.
In all centers, colonoscopy quality was ensured following the guidelines of the Spanish
Gastroenterological Association and the Spanish Society for Digestive Endoscopy [21]. All
endoscopists involved in the study had personal experience of more than 200 colonoscopies
per year and findings were documented in a standardized report form [20]. The quality of
bowel preparation for each colonic segment was categorized as excellent or good versus poor
or bad, as previously described [22]. Cases not meeting these requirements or with unexplored
cecum were re-scheduled for colonoscopy.
At colonoscopy, the number and size of polyps were recorded. Polyps were classified
according to proximal or distal location with respect to the splenic flexure. Adenomas10
mm in size, with tubulovillous architecture, high-grade dysplasia or intramucosal carcinoma
were classified as advanced adenomas. The presence of malignant cells observed beyond the
muscularis mucosa was considered evidence of invasive cancer. Advanced neoplasia was
defined as three or more non-advanced adenomas, advanced adenoma or invasive cancer.
Patients were classified according to the most advanced lesion.
Sample Size and Data Analysis
The risk of advanced adenoma and advanced neoplasia according to familial- or average-risk
was the main study outcome measure. As the familial-risk population comprised individuals
with different neoplastic risk, we estimated the sample size needed to yield sufficient statistical
power for significant results with respect to the main outcome measure in the least numerous
subgroup, i.e., FDR with two FDR diagnosed with colorectal cancer at any age. Considering a
ratio of 10:1 for one versus two relatives affected, an advanced adenoma detection rate of 7.8%
Risk of Colorectal Neoplasia According to Family History
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in individuals with one FDR and 14.7% in those with two FDR with colorectal cancer, with an
alpha error of 0.05 (two-sided) and a beta error of 0.10, the number of individuals having two
FDR with colorectal cancer required was 235. Individuals having one family member with colo-
rectal cancer diagnosed at<60 or60 y were analyzed separately, as an age threshold of 60 y
in the index-case is considered a colorectal cancer risk factor for their relatives [1,6,12].
Between-group differences in the risk of neoplastic lesions with respect to both overall or
colon side-specific colorectal neoplasia detection rates were analyzed by multinomial logistic
regression analysis when considering the 4-level categorical variables (normal colonoscopy,
non-advanced adenoma, advanced adenoma, and cancer). In these analyses, the most severe
colonoscopic finding was represented as an independent category. Binary logistic regression
analysis was used when considering another colonoscopic findings included in the previous
4-level categorical variable. All logistic regression analyses were adjusted for age, gender, and
center and reported as odds ratios (OR) with 95% confidence intervals (CI) [23].
A logistic regression model was developed to predict the probability of advanced neoplasia
according to age, gender and familial groups. The observed frequencies and probabilities pre-
dicted from the regression equation were graphically represented stratifying individuals in 10-y
subsets (20 to 70 for the affected familial groups, 50 to 70 for the control group) and by gender.
The analysis of resources, based on the number of colonoscopies needed to detect one
advanced neoplasia, was performed by inverse marginal probability estimated by binary logistic
regression analysis [24], adjusted for age and center. All analyses were performed using SPSS
version 15.0 (SPSS Inc., Chicago, IL, United States) and STATA version 13.1 (Stata Corp, TX,
US) software. All statistical tests were two-sided, and p-values<0.05 were considered statisti-
cally significant. STROBE guidelines were followed (S1 Text).
Results
Study Population
Overall, 8,498 individuals were assessed for eligibility, of whom 4,175 (49.1%) were assigned to
the familial-risk group and 4,323 (50.9%) to the average-risk group. Of these, 1,160 (27.8%)
individuals having FDR with colorectal cancer and 1,285 (29.7%) average-risk individuals were
excluded (Fig 1) for a total of 3,015 individuals with familial-risk and 3,038 individuals with
average-risk included in the analyses.
Demographic data of the familial-risk cohort are shown in Table 1.
The number of index-cases was 2,474 (median age 66.2 y). Of these, 1,399 (56.5%) were
male and 786 (31.7%) were aged<60 y at diagnosis of colorectal cancer. Siblings with colorectal
cancer predominated among individuals having two FDR affected compared to individuals hav-
ing only one FDR with colorectal cancer (77.7% versus 25.5%, p< 0.001) (Table 1). Compared
to average risk individuals, mean age of the familial-risk individuals was lower (51.8 ± 9.0 versus
59.3 ± 5.5 y, p< 0.001), as was the proportion of men (41.3% versus 47.6%, p< 0.001), as
shown in Table 1.
Risk of Advanced Neoplasia
Colonoscopy findings are shown in Fig 1. Compared to average-risk individuals, in individuals
having two FDR with colorectal cancer, we observed a higher prevalence and risk of non-
advanced adenoma (OR 1.40; 95% CI 1.02 to 1.92, p = 0.03), advanced adenoma (OR 2.13; 95%
CI 1.42 to 3.19, p< 0.001), three or more non-advanced adenomas (OR 2.16, 95% CI 1.21 to
3.84, p = 0.01), and advanced neoplasia (OR 1.90; 95% CI 1.36 to 2.66, p< 0.001) after adjust-
ing for age, sex, and center (Table 2).
The probability of advanced neoplasia increased with age in both cohorts, as expected (Fig 2).
Risk of Colorectal Neoplasia According to Family History
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The prevalence and risk of advanced neoplasia was markedly greater in men than in women
in all groups (Table 3) and at each age interval (Fig 2).
Men and women having one FDR with colorectal cancer consistently showed a similar
probability of advanced neoplasia than average-risk men and women, respectively (Fig 2).
Interestingly, after the age of 50 y, advanced neoplasia was over 2-fold higher (OR 2.50; 95% CI
1.36–2.66, p< 0.001) and developed at least 10 y earlier in men compared to women in the
subgroup of individuals having two FDR with colorectal cancer, (Fig 2 and Table 4).
Individuals having two FDR with colorectal cancer showed a significantly higher prevalence
and risk of advanced adenomas than average-risk individuals both in distal (OR 2.08; 95% CI
1.35 to 3.19, p = 0.001) and proximal colon (OR 1.92; 95% CI 1.08 to 3.40, p = 0.026) (Table 5).
No differences in the prevalence and risk of advanced adenomas categorized by location
were observed for individuals having only one FDR with colorectal cancer compared to aver-
age-risk individuals.
Analysis of Resources
The number of colonoscopies needed to detect one advanced neoplasia was 7 (95% CI 5.4 to
10) in individuals having two FDR with colorectal cancer, 10.6 (95% CI 9.2 to 12.6) in individu-
als having only one FDR with colorectal cancer diagnosed at<60 y, 9 (95% CI 7.2 to 11.6) in
individuals having one FDR diagnosed at >=60 y, and 11.6 (95% CI 10.4 to 13) in average-risk
individuals. Approximately 2-fold fewer colonoscopies were needed to detect one advanced
neoplasia in men than in women in all groups (Table 6).
Discussion
The current study adds new insight on the risk and probability of colorectal neoplasia in the
familial-risk population. Men and women having two FDR with colorectal cancer showed a
Table 1. Demographic data.
Category Average-risk
individuals
One FDR with
CRC diagnosed
at 60 y
One FDR with CRC
diagnosed at <60 y
Two FDR with CRC
diagnosed at any
age
Total
Age group (y), n (%)
< 40 NA NA 43 (2.3) 96 (11.6) 9 (3.0) 148 (2.4)
40 to 49 NA NA 747 (39.6) 315 (37.9) 68 (22.7) 1,130 (18.7)
50 to 59 1,551 (51.1) 666 (35.4) 267 (32.1) 107 (35.7) 2,591 (42.8)
60 to 69 1,487 (48.9) 428 (22.7) 153 (18.4) 116 (38.7) 2,184 (36.1)
Total 3,038 (100) 1,884 (100) 831 (100) 300 (100) 6,053 (100)
Mean age ± SD, y 59.3 ± 5.5 52.1 ± 8.5 49.7 ± 9.6 55.5 ± 8.9 55.6 ± 8.3
Gender, n (%)
Female 1,591 (52.4) 1,107 (58.8) 486 (58.5) 177 (59.0) 3,361 (55.5)
Male 1,447 (47.6) 777 (41.2) 345 (41.5) 123 (41.0) 2,692 (44.5)
Kinship, n (%)a
Parents NA NA 1,640 (87) 362 (43.6) 232 (77.3) 2,234 (36.9)
Siblings NA NA 243 (12.9) 450 (54.2) 233 (77.7) 926 (15.3)
Offspring NA NA 1 (0.1) 19 (2.3) 3 (1) 23 (0.4)
FDR = first-degree relatives; CRC = colorectal cancer; NA = not applicable
a The total numbers in each category may exceed the total number of individuals because first-degree relatives may have more than one close relative
with CRC.
doi:10.1371/journal.pmed.1002008.t001
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significantly greater risk of advanced adenomas and advanced neoplasia than those with
average-risk. In contrast, men and women having one FDR with colorectal cancer showed a
similar risk of these lesions to average-risk individuals, regardless of index-case age at diagnosis
of colorectal cancer. The risk of advanced neoplasia was almost 3-fold higher and appeared at
least 10 y earlier in men than in women in both the familial- and average-risk groups.
Advanced adenoma and early colorectal cancer are surrogate endpoints of colorectal cancer
screening because the detection and treatment of these lesions is associated with a significant
reduction of colorectal cancer incidence and mortality [25,26]. Based on this principle, and on
population-based studies reporting that FDR of patients with colorectal cancer have a higher
relative risk of developing the disease than the average-risk population [12,27,28], current
guidelines recommend screening colonoscopy every 5 [3,4,6–8,29] or 10 [3] y, depending on
whether colorectal cancer in the index-case is diagnosed at<60 or60 y. However, there is no
clear evidence that the natural history of pre-cancerous lesions and cancer differs between
familial- and average-risk populations. In this regard, the risk of adenoma recurrence is more
related to the characteristics of the neoplasia at baseline colonoscopy and to demographic data
(age and gender) than to family history, suggesting that screening intervals in individuals with
familial colorectal cancer could be extended beyond 5 y, as most guidelines recommend [30,31].
Previous case-control studies have shown contradictory results with respect to adenoma
prevalence in familial colorectal cancer. At least two studies [32,33] have reported a similar
Table 2. Risk of colorectal neoplasia in familial- and average-risk groups.
Most advanced lesion Screening group n ORa 95% CI p-value
Non-advanced adenoma Average-risk individuals 581 1 b
One FDR with CRC diagnosed at  60 y 339 1.18 0.99 to 1.40 0.05
One FDR with CRC diagnosed at < 60 y 123 1.07 0.84 to 1.35 0.56
Two FDR with CRC diagnosed at any age 63 1.40 1.02 to 1.92 0.03
Advanced adenoma c Average-risk individuals 303 1 b
One FDR with CRC diagnosed at  60 y 122 1.09 0.85 to 1.40 0.49
One FDR with CRC diagnosed at < 60 y 57 1.30 0.93 to 1.81 0.12
Two FDR with CRC diagnosed at any age 35 2.13 1.42 to 3.19 <0.001
3 Non-advanced adenomas Average-risk individuals 99 1 b
One FDR with CRC diagnosed at  60 y 45 0.93 0.62 to 1.38 0.72
One FDR with CRC diagnosed at < 60 y 16 0.84 0.47 to 1.50 0.56
Two FDR with CRC diagnosed at any age 16 2.16 1.21 to 3.84 0.01
Cancer Average-risk individuals 25 1 b
One FDR with CRC diagnosed at  60 y 14 1.61 0.80 to 3.25 0.17
One FDR with CRC diagnosed at < 60 y 8 2.31 0.98 to 5.42 0.05
Two FDR with CRC diagnosed at any age 2 1.18 0.26 to 5.18 0.82
Advanced neoplasiad Average-risk individuals 427 1 b
One FDR with CRC diagnosed at  60 y 181 1.03 0.83 to 1.27 0.77
One FDR with CRC diagnosed at < 60 y 81 1.19 0.90 to 1.58 0.20
Two FDR with CRC diagnosed at any age 53 1.90 1.36 to 2.66 <0.001
OR = odds ratio; CI = confidence interval; FDR = first-degree relatives; CRC = colorectal cancer.
a adjusted for age, gender and participating center.
b Reference category.
c Advanced adenoma included adenoma 10 mm in diameter, with tubulovillous architecture or with high-grade dysplasia.
d Advanced neoplasia included advanced adenoma, three or more non-advanced adenomas or CRC. Comparisons with the reference group were carried
out using multiple binary logistic regression analysis.
doi:10.1371/journal.pmed.1002008.t002
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prevalence of adenomas in individuals having one FDR with colorectal cancer compared with
average-risk individuals. In contrast, other studies have shown an increased prevalence of
advanced adenomas in FDR of patients with colorectal cancer compared with average-risk
individuals [11–13,34,35]. However, some of these studies had important methodological
flaws: first, the control group was small in most of them [13,32,33,35] and frequently inappro-
priate, including autopsies [10], symptomatic patients [35], or volunteers paying for screening
colonoscopy [13]. Second, the small sample size did not allow stratification according to the
number of FDR affected [13,32,33,35]. Third, their retrospective design did not allow for ascer-
taining the indication for colonoscopy and exclusion of patients with hereditary colorectal can-
cer syndromes [11,12]. Finally, high-quality colonoscopy was not specifically assessed in many
studies [10–12,32,33].
Our study apparently solved these drawbacks, corroborating that among relatives of patients
with colorectal cancer, only those with two FDR affected showed a marked increase in the prev-
alence and risk of both adenomas and cancer compared with average-risk individuals in both
the proximal and the distal colon. However, the risk of advanced neoplasia in individuals hav-
ing only one FDR with colorectal cancer diagnosed before or after the age of 60 y was similar to
that of average-risk individuals. These findings are in line with the results of a nested study per-
formed within the randomized controlled Prostate, Lung, Colorectal, and Ovarian (PLCO)
cancer-screening trial of flexible sigmoidoscopy versus usual care, showing that men and
women having two FDR with colorectal cancer had a 2-fold increased risk of incident colorec-
tal cancer, whereas those with one FDR affected were not associated with an increased risk in
colorectal cancer incidence or mortality, regardless of their age at the time of diagnosis [36].
Interestingly, we observed that individuals with two FDR had also an increased risk of both
non-advanced and advanced-adenomas compared with average-risk individuals. In addition,
men showed an almost 3-fold higher risk of advanced neoplasia than women in all groups, and
Fig 2. Predicted probabilities of advanced colorectal neoplasia according to age and gender.Women
(left) and men (right). A logistic regression model was developed to predict the probability of advanced
neoplasia according to age. The observed frequencies and probabilities predicted from the regression
equation were graphically represented, stratifying individuals in 10-y subsets (from 20 to 70 y for the affected
familial groups, and from 50 to 70 y for the control group). Vertical lines mark the corresponding 95%
confidence intervals.
doi:10.1371/journal.pmed.1002008.g002
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advanced neoplasia appeared at least 10 y earlier in men than in women. It is interesting to
note that the number of colonoscopies needed to detect one advanced neoplasia was 2-fold
higher in women than in men at all ages in both cohorts. Taken together, our results support
the notion that screening colonoscopy may be delayed at least 10 y in women having one or
even two FDR with colorectal cancer, as has been shown for women in the average-risk popula-
tion [37–39].
Our study has several strengths. First, participants were recruited with strict selection crite-
ria regarding colonoscopy quality and inclusion age. Only individuals with a first lifetime com-
plete colonoscopy were eligible and an upper age limit of 69 y was established to minimize the
effect of age on the risk of advanced neoplasia. Second, colonoscopies were performed by the
same endoscopists who applied the same quality criteria in both cohorts. Third, to our knowl-
edge, this is the largest study to compare the risk of advanced neoplasia between asymptomatic
FDR of patients with colorectal cancer and average-risk individuals, thus allowing an accurate
estimation of this parameter according to the number of close relatives with colorectal cancer,
gender, and index-case age at diagnosis of the disease.
The study also has certain limitations. First, although average-risk individuals were consecu-
tively included in the COLONPREV study [20] this was not the case in the familial-risk group.
Fifty-five percent of the FDR were consecutively included in two prospective studies [18,19],
whereas the remaining FDR were not. However, demographic characteristics and risk of
Table 3. Risk of colorectal neoplasia according to gender in familial- and average-risk groups.
Most advanced lesion Screening group n Men Women ORa 95% CI p-value
Non-advanced adenoma Average-risk individuals 581 326 255 1.52 1.26 to 1.82 <0.001
One FDR with CRC diagnosed at 60 y 339 162 177 1.42 1.12 to 1.81 0.004
One FDR with CRC diagnosed at <60 y 123 55 68 1.23 0.87 to 1.82 0.306
Two FDR with CRC diagnosed at any age 63 24 39 0.91 0.50 to 1.64 0.763
Advanced adenomab Average-risk individuals 303 206 97 2.66 2.06 to 3.44 <0.001
One FDR with CRC diagnosed at 60 y 122 77 45 2.65 1.80 to 3.88 <0.001
One FDR with CRC diagnosed at <60 y 57 32 25 2.02 1.16 to 3.51 0.013
Two FDR with CRC diagnosed at any age 35 19 16 1.88 0.90 to 3.91 0.088
3 Non-advanced Adenomas Average-risk individuals 99 74 25 3.33 2.10 to 5.28 <0.001
One FDR with CRC diagnosed at 60 y 45 32 13 3.73 1.94 to 7.18 <0.001
One FDR with CRC diagnosed at <60 y 16 13 3 7.24 2.01 to 26.09 0.002
Two FDR with CRC at any age 16 11 5 3.59 1.20 to 10.79 0.022
Cancer Average-risk individuals 25 17 8 2.42 1.03 to 5.66 0.041
One FDR with CRC diagnosed at 60 y 14 10 4 3.78 1.16 to 12.24 0.027
One FDR with CRC diagnosed at <60 y 8 4 4 1.42 0.34 to 5.84 0.623
Two FDR with CRC diagnosed at any age 2 1 1 2.08 0.11 to 39.08 0.622
Advanced neoplasiac Average-risk individuals 427 297 130 2.99 2.39 to 3.74 <0.001
One FDR with CRC diagnosed at 60 y 181 119 62 3.16 2.28 to 4.37 <0.001
One FDR with CRC diagnosed at <60 y 81 49 32 2.57 1.59 to 4.17 <0.001
Two FDR with CRC diagnosed at any age 53 31 22 2.50 1.34 to 4.65 0.004
CI = confidence interval; FDR = first-degree relatives; CRC = colorectal cancer; OR = odds ratio.
a Odds ratio compared men versus women, adjusted for age and participating center.
b Advanced adenoma included adenoma 10 mm in diameter, with tubulovillous architecture or with high-grade dysplasia.
c Advanced neoplasia included advanced adenoma, three or more non-advanced adenomas or CRC. Comparisons with the reference group were carried
out using multiple binary logistic regression analysis.
doi:10.1371/journal.pmed.1002008.t003
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advanced neoplasia were similar in FDR regardless of whether they were included consecu-
tively or not (S1 Table). This potential bias was also minimized by performing a logistic regres-
sion analysis, controlling for confounding factors. Second, due to the study design, there was a
substantial difference in age between individuals with family history of colorectal cancer and
average risk individuals. Both logistic regression analyses and stratification by age suggested
Table 4. Advanced adenomasa and advanced neoplasiab found at colonoscopy according to age and gender.
Age-group (y) Average-risk individuals One FDR with CRC
diagnosed at 60 y
One FDR with CRC
diagnosed at <60 y
Two FDRs with CRC
diagnosed at any age
Category Men Women Men Women Men Women Men Women
20–29 (n = 19) Advanced adenoma, n (%) N/A N/A 0/1 (0) 0/2 (0) 0/7 (0) 0/8 (0) 0/1 (0) 0/0 (0)
Advanced neoplasia, n (%) N/A N/A 0/1 (0) 0/2 (0) 0/7 (0) 0/8 (0) 0/1 (0) 0/0 (0)
30–39 (n = 132) Advanced adenoma, n (%) N/A N/A 1/17 (5.9) 0/26 (0) 2/46 (4.3) 1/35 (2.9) 0/4 (0) 1/4 (25)
Advanced neoplasia, n (%) N/A N/A 2/17 (11.8) 0/26 (0) 2/46 (4.3) 2/35 (5.7) 1/4 (25) 1/4 (25)
40–49 (n = 1,130) Advanced adenoma, n (%) N/A N/A 24/326 (7.4) 13/424 (3.1) 4/124 (3.2) 6/192 (3.1) 4/32 (12.5) 1/36 (2.8)
Advanced neoplasia, n (%) N/A N/A 36/326 (11.0) 13/424 (3.1) 7/124 (5.6) 7/192 (3.6) 4/32 (12.5) 4/36 (11.1)
50–59 (n = 2,591) Advanced adenoma, n (%) 90/756 (11.9) 47/795 (5.9) 30/262 (11.5) 21/409 (5.1) 14/99 (14.1) 13/171 (7.6) 8/44 (18.2) 6/65 (9.2)
Advanced neoplasia, n (%) 124/756 (16.4) 65/795 (8.2) 43/262 (16.4) 31/409 (7.6) 22/99 (22) 15/171 (8.8) 14/44 (31.8) 7/65 (10.8)
60–69 (n = 2,184) Advanced adenoma, n (%) 116/691 (16.8) 50/796 (6.3) 22/174 (12.6) 11/255 (4.3) 12/70 (17.1) 6/84 (7.1) 8/45 (17.8) 8/72 (11.4)
Advanced neoplasia, n (%) 173/691 (25.0) 65/796 (8.2) 38/174 (21.8) 18/255 (7.1) 18/70 (25.7) 9/84 (10.7) 13/45 (28.9) 10 /72(13.9)
FDR = asymptomatic first-degree relatives aged 40 to 69 or 10 y earlier than the youngest case with CRC in the family; CRC = colorectal cancer
a Advanced adenoma included adenoma 10 mm in diameter, with tubulovillous architecture or with high-grade dysplasia.
b Advanced neoplasia included advanced adenoma, three or more non-advanced adenomas, or CRC
doi:10.1371/journal.pmed.1002008.t004
Table 5. Risk of advanced adenomaa stratified by location of lesionb.
Category Screening group Individuals with advanced adenoma, n ORc 95% CI p-value
Overall Average-risk individuals (n = 3,038) 303 1d
One FDR having CRC diagnosed at 60 y (n = 1,884) 122 1.03 0.81 to 1.32 0.774
One FDR having CRC diagnosed at <60 y (n = 831) 57 1.24 0.89 to 1.72 0.195
Two FDRs having CRC diagnosed at any age (n = 300) 35 1.86 1.26 to 2.76 0.002
Distal Average-risk individuals (n = 3,038) 231 1d
One FDR having CRC diagnosed at 60 y (n = 1,884) 99 1.35 0.86 to 1.49 0.360
One FDR having CRC diagnosed at <60 y (n = 831) 45 1.33 0.93 to 1.92 0.117
Two FDRs having CRC diagnosed at any age (n = 300) 29 2.08 1.35 to 3.19 0.001
Proximal Average-risk individuals (n = 3,038) 130 1d
One FDR having CRC diagnosed at 60 y (n = 1,884) 41 0.89 0.60 to 1.31 0.564
One FDR having CRC diagnosed at <60 y (n = 831) 18 1.00 0.59 to 1.72 0.988
Two FDRs having CRC diagnosed at any age (n = 300) 15 1.92 1.08 to 3.40 0.026
FDR = asymptomatic first-degree relatives aged 40 to 69 or 10 y earlier than the youngest case with CRC in the family; CRC = colorectal cancer;
CI = confidence interval.
a Advanced adenoma included adenomas >10 mm in diameter, with tubulovillous architecture or with high-degree dysplasia.
b Neoplasm location was established with respect to the splenic flexure; the total number of individuals with proximal and distal lesions may exceed the
total number of individuals because individuals could have lesions in both locations.
cAdjusted by age, gender, and center.
d Reference category.
doi:10.1371/journal.pmed.1002008.t005
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that age was not a main confounding factor in this study (S2 Table). However we cannot
exclude an immortal time bias in the study. The risk of bias is built into the study design in a
way that cannot be compensated by including an interaction test for age. Third, other con-
founding factors such as nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, smoking,
obesity, and diet were not recorded, and they could conceivably have influenced the results.
Fourth, unfortunately, the prevalence of serrated polyps was not recorded because at the time
the present study was initiated, classification of serrated polyps was still under debate. In fact,
only recently clinical guidelines recommend colonoscopy surveillance for individuals with ser-
rated polyps [1]. Fifth, colorectal cancer family history was obtained by interview and therefore
could be underreported [40]. Additionally, the effect of the number of colorectal cancers in
relation to the family size could not be analyzed. Sixth, although adenoma detection rate is
widely used as a colonoscopy quality indicator, unfortunately this information was not avail-
able. Since the centers that provided individuals in the average-risk group (COLONPREV) and
the ones that recruited individuals in the familial-risk cohort are virtually the same, we do not
expect differences in colonoscopy quality between the two cohorts. Finally, some of the individ-
uals included may have been members of families with Lynch syndrome, since we did not sys-
tematically exclude DNAmismatch repair deficiency in all cases with colorectal cancer.
However, the overall results should not be greatly affected since this possibility would only
involve a small number of individuals.
Our findings suggest that screening guidelines for the management of familial colorectal
cancer, if not adjusted for the number of relatives affected and sex, may substantially overesti-
mate the prevalence of advanced neoplasia, particularly in men and women having one FDR
with colorectal cancer and in women having two FDR with colorectal cancer diagnosed before
the age of 50. In fact, the same screening strategy as that for average-risk individuals could be
recommended to men and women having only one FDR with colorectal cancer, but starting at
the age of 40 or 45 y, in line with the results of previous studies [5,30], thus avoiding overuse of
screening colonoscopy. In support of this recommendation, there are two recent prospective
studies demonstrating that fecal immunochemical testing is as effective as colonoscopy to
detect advanced neoplasia in colorectal cancer associated with familial risk [19,41]. In contrast,
the higher prevalence and earlier presentation of advanced neoplasia in men having two FDR
Table 6. Number of colonoscopies needed to detect one advanced adenomaa and one advanced neoplasiab according to familial risk.
Category Average-risk
individuals n (95% CI)
One FDR with CRC diagnosed
at <60 y n (95% CI)
One FDR with CRC diagnosed
at 60 y n (95% CI)
Two FDRs with CRC diagnosed
at any age n (95% CI)
Advanced
adenoma
Men 7.9 (7.0 to 9.1) 7.6 (6.3 to 9.7) 7.2 (5.5 to 10.5) 5.1 (3.7 to 8.4)
Women 19.9 (16.6 to 24.8) 19.3 (15.0 to 27.0) 13.6 (9.9 to 21.8) 9.4 (6.5 to17.3)
Global 12.0 (10.8 to 13.5) 11.6 (9.9 to 14.0) 9.8 (7.8 to 13.0) 6.9 (5.3 to 9.8)
Advanced
neoplasia
Men 7.8 (7.0 to 9.0) 7.2 (6.0 to 8.8) 6.8 (5.2 to 9.8) 5.4 (4.0 to 8.8)
Women 18.8 (15.8 to 23.2) 17.8 (14.0 to 24.6) 11.8 (8.8 to 18.2) 9.4 (6.4 to16.8)
Global 11.6 (10.4 to 13) 10.6 (9.2 to 12.6) 9.0 (7.2 to 11.6) 7.0 (5.4 to 10.0)
FDR = asymptomatic first-degree relatives aged 40 to 69 or 10 y younger than the youngest case with CRC in the family; CRC = colorectal cancer;
CI = confidence interval.
aAdvanced adenoma included adenomas >10 mm in diameter, with tubulovillous architecture or with high-degree dysplasia.
bAdvanced neoplasia included advanced adenoma, three or more non-advanced adenomas, or CRC.
doi:10.1371/journal.pmed.1002008.t006
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with colorectal cancer suggest that men have higher genetic penetrance, thus supporting
screening colonoscopy from the age of 40, whereas it could be delayed until the age of 50 or
older in women with two FDR.
In conclusion, our study demonstrates that the risk and predicted probability of advanced
neoplasia are markedly increased in individuals having two FDR with colorectal cancer com-
pared to average-risk individuals, but not in individuals having only one FDR with colorectal
cancer, regardless of when they were diagnosed. Our results suggest that men having two FDR
with colorectal cancer may benefit from an early screening colonoscopy (i.e., 40 y old or 10 y
before the youngest case in the immediate family), whereas individuals having only one FDR
with colorectal cancer could be recommended to undergo the same screening strategy as the
average-risk population.
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Editors' Summary
Background
Colorectal cancer kills about 700,000 people worldwide every year. This common cancer
develops when one of the epithelial cells that lines the colon (the final part of the digestive
system; also known as the large intestine or large bowel) or the rectum (the lower end of
the colon) acquires genetic changes that allow it to divide uncontrollably to form a tumor
(lump), to invade surrounding tissues, and to move around the body (metastasize). Symp-
toms of colorectal cancer include weight loss, blood in the stool, and changed bowel habits.
Treatments for the condition include surgery, chemotherapy, and radiation. As with all
types of cancer, these treatments are more likely to be successful if started when the tumor
is small and before it has invaded surrounding tissues. Consequently, many countries run
screening programs to detect the earliest signs of colorectal cancer in apparently healthy
people.
WhyWas This Study Done?
One of the methods used to screen for colorectal cancer is colonoscopy—visual examina-
tion of the colonic lining using a tube-like instrument that is inserted through the rectum
into the colon. Colonoscopy also detects adenomas (polyps), benign tumors that lack the
ability to invade or metastasize. It is important to find and remove adenomas because
these growths can develop into colorectal cancers. In the United States, colonoscopy is rec-
ommended every 10 y for everyone in the general population over 50 y old. However, the
first-degree relatives (parents, siblings, or child) of patients with colorectal cancer have a
higher risk of developing colorectal cancer than people in the general population. So, cur-
rent screening guidelines in the US and elsewhere recommend colonoscopy every 5 or 10 y
from age 40 for people who have a first-degree relative diagnosed with colorectal cancer,
depending on whether the relative’s colorectal cancer was diagnosed before or after the age
of 60, respectively. Notably, no large-scale studies have compared the risk of adenomas in
symptom-free people with first-degree relatives with colorectal cancer with the risk in
symptom-free average-risk people. This large multicenter cross-sectional study (a study
that looks at a single time point) aims to remedy this deficit in the evidence base.
What Did the Researchers Do and Find?
The researchers enrolled 3,015 first-degree relatives of patients with colorectal cancer and
3,038 average-risk individuals, all of whom were undergoing their first screening colonos-
copy in Spain. They divided the familial-risk cohort into two groups. The 1-FDR group
comprised people with one first-degree relative diagnosed with colorectal cancer at60 y
or at<60 y. The 2-FDR group comprised individuals with two first-degree relatives diag-
nosed with colorectal cancer at any age. They then compared the risk of advanced neopla-
sia (three or more non-advanced adenomas, advanced adenoma, or invasive cancer) in the
different groups after adjusting for age and sex (confounding factors that affect an individ-
ual’s risk of colorectal cancer). Advanced neoplasia was more prevalent (present in a
higher proportion of the population) in the 2-FDR group than in average-risk individuals;
individuals in the 2-FDR group were nearly twice as likely to have advanced neoplasia as
average-risk individuals. Compared to average-risk individuals, individuals with 1-FDR
diagnosed at60 y and at<60 y had no increased risk of advanced neoplasias. Notably,
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after age 50, men developed advanced neoplasias over 2-fold more frequently than
women, and advanced neoplasias appeared at least 10 y earlier in men than in women.
What Do These Findings Mean?
These findings suggest that the risk of advanced neoplasia is markedly increased in indi-
viduals having two first-degree relatives with colorectal cancer compared to average-risk
individuals but not in individuals having only one affected first-degree relative. They also
suggest that men have a 2-fold higher risk of advanced neoplasia than women, indepen-
dent of family history. Several aspects of the study design may affect the accuracy of these
findings. For example, the average-risk study participants were older than the participants
with first-degree relatives with colorectal cancer, and different approaches were used to
enroll the two sets of participants, which may have introduced some bias. Nevertheless,
these findings suggest that the guidelines for screening for colorectal cancer should be
revised. Specifically, they suggest that men with two first-degree relatives with colorectal
cancer may benefit from early screening colonoscopy but that the screening strategy rec-
ommended for the average-risk population may be appropriate for individuals with only
one first-degree relative with colorectal cancer.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1002008.
• The US National Cancer Institute provides information for patients about all aspects of
colorectal cancer, including information on tests to detect colorectal cancer; it also pro-
vides more detailed information about the condition and about screening for health pro-
fessionals (in English and Spanish)
• The United Kingdom National Health Service Choices website has information about
colorectal cancer (including some personal stories) and information on screening for
colorectal cancer
• The not-for-profit organization Cancer Research UK also provides information about
colorectal cancer
• Details of colorectal cancer screening guidelines in the US and in the UK are available
• MedlinePlus provides links to further resources about colorectal cancer (in English and
Spanish) and has a page about colorectal adenomas
Risk of Colorectal Neoplasia According to Family History
PLOSMedicine | DOI:10.1371/journal.pmed.1002008 May 3, 2016 18 / 18
